Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

OTC Awards

- PMLiVE

Boehringer eyes rare disease use for respiratory blockbuster

Would help support respiratory franchise

- PMLiVE

Bedrock Group announces the launch of Origins, a health experience research company

Bedrock Group is proud to announce the launch of Origins, a health experience research company.

Bedrock Healthcare Communications

Graphic inspired by back to the future

The Exhibition Hall: Past, Present and Future

As I sit here at another pharma conference, I start to reflect on how they have changed over the years.

Cuttsy + Cuttsy

- PMLiVE

Keytruda monotherapy fails in triple negative breast cancer

Fails in gambit to outflank rival Tecentriq

- PMLiVE

Health comms agency emotive hires new cell and gene therapy leader

New division will cater to fast-expanding field

- PMLiVE

RNA-focused biotech Storm Therapeutics raises extra £14m

New head of translational oncology also hired

- PMLiVE

Europe responding to gene therapy challenge, but picture remains fragmented

Germany, Italy and England using outcomes-based deals

- PMLiVE

Syncona launches another cell therapy company, Treg specialist Quell

Focuses on novel immune system approach

Turning learning into action 2

Turning learning into action: The challenge of behaviour change

We all learn differently In order to optimise the sharing and acquisition of new knowledge, different modes of learning need to be leveraged. For example, the behaviourism, cognitivism and constructivism...

Porterhouse Medical Group

- PMLiVE

MorphoSys eyes 2020 launch for lymphoma CAR-T challenger

Results rival Kymriah and Yescarta - with less cost and complexity

- PMLiVE

There is no such thing as good medical communications

By Toby O'Brien

- PMLiVE

So far so good for Amgen’s much-anticipated KRAS inhibitor

Promise to hit previously 'undruggable' target

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links